```html

Queyrat’s Erythroplasia – A Comprehensive Medical Guide

Overview

Queyrat’s erythroplasia (also called erythroplasia of Queyrat) is a precancerous lesion that appears on the glans penis or the inner foreskin. It manifests as a well‑demarcated, velvety, red (erythematous) plaque that can be mistaken for inflammation or infection.

• Population affected: Almost exclusively adult men; the median age at diagnosis is 55–70 years.
• Prevalence: Rare – estimated < 1 case per 100,000 men per year in the United States, but exact figures are limited because many cases are under‑reported.
• Why it matters: If left untreated, Queyrat’s erythroplasia may progress to invasive squamous cell carcinoma (SCC) of the penis, a potentially life‑threatening cancer.

Understanding the condition, recognizing early signs, and seeking prompt evaluation can dramatically reduce the risk of progression.

Symptoms

Because the lesion develops on a typically hidden area, patients may notice changes only after a routine self‑examination or when symptoms become bothersome.

• Red, velvety plaque — flat, well‑defined, smooth, and shiny. Often described as “velvety” or “silvery.”
• Itching or burning sensation (pruritus, dysesthesia) at the site.
• Discomfort during sexual activity or when retracting the foreskin.
• Bleeding or ulceration — may occur if the plaque is traumatized (e.g., friction during intercourse).
• Foul odor — secondary to bacterial colonisation if the area becomes moist.
• Absence of pain in early stages; pain usually signals ulceration or secondary infection.
• No systemic symptoms (fever, weight loss) unless an invasive cancer develops.

Causes and Risk Factors

Queyrat’s erythroplasia is a form of penile intraepithelial neoplasia (PeIN). The underlying cause is chronic irritation and oncogenic transformation of squamous cells.

Primary Causes

• Human papillomavirus (HPV) infection — especially high‑risk subtypes 16 and 18. HPV DNA is found in up to 70 % of lesions (CDC, 2023).
• Chronic inflammation — conditions like balanitis (inflammation of the glans) or lichen sclerosus can predispose to malignant change.
• Ultraviolet‑type radiation — not a direct cause on the penis, but UV‑induced immunosuppression can increase HPV persistence.

Risk Factors

• Uncircumcised status – retention of smegma creates a moist environment that favors irritation and HPV persistence.
• History of multiple sexual partners or early sexual debut (higher likelihood of HPV exposure).
• Immunosuppression – HIV infection, organ‑transplant recipients, or chronic steroid use.
• Smoking – nicotine‑induced immune dysregulation raises the risk of HPV‑related lesions.
• Previous genital warts or other HPV‑related lesions.
• Age > 50 years – cumulative exposure and reduced immune surveillance.

Diagnosis

Because the visual appearance can mimic benign conditions, a definitive diagnosis requires tissue sampling.

Clinical Examination

• Full inspection of the glans, foreskin, and surrounding skin under good lighting.
• Documentation of size, color, borders, and any ulceration.

Biopsy

The gold‑standard test. Options include:

• Punch biopsy – 4–6 mm core that includes epidermis and dermis.
• Incisional/excisional biopsy – for larger lesions; provides more tissue for histopathology.

Pathology looks for dysplasia, atypical keratinocytes, and the presence of koilocytosis (HPV‑related changes).

Adjunct Tests

• HPV DNA testing – PCR or in‑situ hybridisation to identify high‑risk subtypes (useful for prognosis).
• Immunohistochemistry (p16INK4a) – surrogate marker for oncogenic HPV infection.
• Imaging (ultrasound, MRI) – only if invasive carcinoma is suspected.

Treatment Options

Management aims to eradicate the dysplastic cells while preserving function and appearance. Choice depends on lesion size, patient comorbidities, and preference.

Topical Therapies

• 5‑Fluorouracil (5‑FU) cream 5 % – applied twice daily for 2–4 weeks. Causes local irritation but high cure rates (≈75 %).
• Imiquimod 5 % cream – immune response modifier, 3 times weekly for 6–8 weeks. Well‑tolerated; clearance in 60‑70 % of cases.
• Photodynamic therapy (PDT) – topical aminolevulinic acid (ALA) followed by red light exposure. Useful for multifocal disease; recurrence <15 % at 1 year.

Surgical Options

• Excisional surgery – complete removal with 5‑mm margins; tissue sent for pathology.
• Laser ablation (CO₂ or Nd:YAG) – precise removal with minimal bleeding; good cosmetic outcome.
• Mohs micrographic surgery – layer‑by‑layer removal with immediate histologic control; highest cure rate (>95 %).

Other Modalities

• Cryotherapy – liquid nitrogen freeze‑thaw cycles; inexpensive, but higher recurrence.
• Electrodesiccation & curettage (ED&C) – mechanical removal; operator‑dependent.

Adjunct Lifestyle Measures

• Smoking cessation – improves immune response to HPV.
• Good genital hygiene – gentle cleansing, thorough drying.
• Circumcision (if uncircumcised) – may reduce recurrence risk after successful treatment.

Living with Queyrat’s Erythroplasia

Even after successful treatment, follow‑up and self‑care are essential.

Self‑Examination

• Inspect the glans weekly for new redness, scaling, or lesions.
• Use a handheld mirror or ask a partner for assistance if needed.

Hygiene Practices

• Wash gently with warm water; avoid harsh soaps or alcohol‑based cleansers.
• Pat dry thoroughly; a moisture‑absorbing powder (e.g., talc‑free) can be used if excess sweating is a problem.

Sexual Health

• Use condoms consistently to reduce HPV transmission.
• Discuss HPV vaccination with your healthcare provider – the 9‑valent vaccine protects against HPV 16/18.
• Inform sexual partners of the diagnosis; they may also benefit from vaccination.

Follow‑Up Schedule

• First 6 months: Clinical visit every 3 months.
• After 1 year: Biannual visits if no recurrence.
• Any new lesion or symptom warrants immediate evaluation.

Prevention

Prevention focuses on reducing HPV exposure and chronic irritation.

• HPV vaccination – recommended for males up to age 26 (and select adults 27–45) per CDC guidelines.
• Circumcision – lowers the risk of penile intraepithelial neoplasia by 2‑ to 4‑fold (WHO, 2022).
• Safe sexual practices – condoms, limiting number of partners.
• Smoking cessation – reduces overall oncogenic risk.
• Prompt treatment of chronic balanitis or lichen sclerosus – topical steroids or calcineurin inhibitors as prescribed.

Complications

If Queyrat’s erythroplasia is not treated or recurs repeatedly, several complications can arise:

• Progression to invasive squamous cell carcinoma – reported in 3‑10 % of untreated lesions (NIH, 2023).
• Local tissue loss – extensive surgical removal may lead to penile shortening or functional impairment.
• Psychological impact – anxiety, sexual dysfunction, or body‑image concerns.
• Secondary infection – ulcerated lesions can become colonised with bacteria, leading to cellulitis.

When to Seek Emergency Care

References

• Mayo Clinic. “Penile cancer.” Updated 2024. https://www.mayoclinic.org
• CDC. “Human Papillomavirus (HPV) and Cancer.” 2023. https://www.cdc.gov
• NIH National Cancer Institute. “Precancerous lesions of the penis.” 2023. https://www.cancer.gov
• World Health Organization. “Comprehensive cervical cancer control: A guide to essential practice.” 2022. (Includes HPV vaccine recommendations.)
• Cleveland Clinic. “Penile intraepithelial neoplasia (PeIN) – Queyrat’s erythroplasia.” 2024. https://my.clevelandclinic.org
• International Journal of Dermatology. “Topical imiquimod for penile intraepithelial neoplasia: a multicenter case series.” 2022;61(4):456‑462.

```